Navigation Links
ImmunoVaccine Technologies Inc. Nears Phase I Clinical Trials with Completion of Scientific Advisory Board
Date:9/27/2007

HALIFAX, Sept. 27 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT) finalizes an important step in its progress with the last appointment to its scientific advisory board (SAB), international oncology expert, Dr. Neil Berinstein.

Dr. Berinstein is the Global Head of the Cancer Vaccine Program at sanofi pasteur, and a professor at the University of Toronto's Department of Medicine. He has a long track record in fundamental research and has a significant publication record in the area of normal and malignant B cell biology, including articles, abstracts and book chapters on immunotherapeutic approaches for cancer including cancer vaccines. He was recently appointed vice-president of the Sabin Institute Cancer vaccine consortium. Dr. Berinstein received an MD from the University of Manitoba, and completed training programs at the University of Toronto in Internal Medicine and Medical Oncology. Following this, he spent four years as a post-doctoral fellow in Dr. Ron Levy's Lab at Stanford University working in the area of immunotherapy for cancer.

"IVT has very promising science," remarked Dr. Berinstein. "Their work is particularly interesting to me, and my commitment to new immunotherapeutic approaches for patients with cancer. "

ImmunoVaccine Technologies Inc. has been actively recruiting members to its SAB in preparation for its Phase I clinical trials, and sees this final appointment as a major stepping stone to that goal.

"This final appointment is one of the last steps before our Phase I clinical trials," said Dr. Martin Kast, chair of the scientific advisory board. "Dr. Berinstein's experience and insight are reflective of the quality of professionals that our exciting projects have attracted," continued Kast.

"Dr. Berinstein is a valuable addition to the team, and represents a pivotal point in our ongoing plan to introduce our patented vaccine platform," commented Dr. Randal Chase, president and CEO of IVT.

ImmunoVaccine Technologies Inc. (IVT) is a vaccine enhancement company focused on the commercialization of its patented VacciMax(R) platform. VacciMax(R) is a novel technology that can aid the development of new vaccines in human health applications with potential for both therapeutic cancer applications and preventative infectious disease vaccines. The opportunities for market applications and medical benefits are broad, and are currently being applied to cervical cancer, with potential for melanoma, breast, prostate and colon cancer treatments, as well as prevention therapies for influenza and other infectious diseases. http://www.immunovaccine.com


'/>"/>
SOURCE ImmunoVaccine Technologies Inc
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Barriers will not stop convergence of medical technologies
2. Merge Technologies net loss doubles to $10.1M
3. Making deals with evolving technologies in mind
4. Third Wave Technologies to raise $14.9M through private debt
5. Meier joins Broadlook Technologies as COO
6. Platypus Technologies secures $450K SBIR grant
7. Napier joins board of Third Wave Technologies
8. aOva Technologies raises $3 million
9. Consumer, business technologies face same challenges
10. Promega to get early access to WARF technologies under new agreement
11. Linda Weber to run Fiservs Interactive Technologies unit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power ... triple negative breast cancer (TNBC), announced today their completion of ... The YEi Start in France ... their business in France and Europe.  ... complete an intensive one week immersion in France ...
(Date:2/16/2017)... 2017   Capricor Therapeutics, Inc. (NASDAQ: ... developing first-in-class biological therapies for cardiac and other ... to terminate its license agreement with the Mayo ... Cenderitide. "Our decision to return these ... our efforts to advance our core cell and ...
(Date:2/16/2017)...  Champions Oncology, Inc. (NASDAQ: CSBR ), ... advanced technology solutions and products to personalize the development ... of new cohorts of PDX models to their existing ... Champions, product line in hepatocellular cancer, breast cancer, castrate ... non-small cell lung cancer (including EGFR mutation; ALK/ROS1 positive) ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... industry leading Biochemistry Services specifically targeting the rapidly growing needs of the ... the biochemical and biosimilar characterization , product-related impurity characterization, aggregation ...
Breaking Biology Technology:
(Date:1/21/2017)... , Jan 20, 2017 Research and ... Biometrics Market 2017-2021" report to their offering. ... The global voice recognition biometrics ... 2017-2021. The report covers the present scenario and ... 2017-2021. To calculate the market size, the report considers the revenue ...
(Date:1/18/2017)... -- In vitro diagnostic (IVD) companies were very active in ... Kalorama Information expects that trend to continue – though ... uncertainty in reimbursement and healthcare reform in ... acquisitions landscape. Instead of looking to buy technology, the ... of their home country and also to increase their ...
(Date:1/12/2017)... SAN DIEGO , Jan. 12, 2017  Trovagene, ... circulating tumor DNA (ctDNA) technologies, today announced that it ... Europe and the Middle ... biopsy tests.  This milestone marks the first wave of ... tests for urine and blood samples. The ...
Breaking Biology News(10 mins):